

Publikationsliste Dr. Boris-A. Kallmann

- 1 **B.A.Kallmann**, V.Burkart, K.-D.Kröncke, V.Kolb-Bachofen, H. Kolb
Toxicity of chemically generated nitric oxide towards pancreatic islet cells can be prevented by nicotinamide.
Life Sciences 1992 ; 51: 671 – 678
- 2 V.Burkart, Y.Imai, **B.A.Kallmann**, H.Kolb
Cyclosporin A protects pancreatic islet cells from nitric oxide-dependent macrophage cytotoxicity.
FEBS Lett. 1992 ; 313: 56-58
- 3 V.Burkart, A.Jalowy, B.Hartmann, **B.A.Kallmann**, K.Fehsel, H.Kolb
Nitric oxide as a mediator of autoimmunity in insulin-dependent diabetes.
Immunobiology 1992; 186 : 19 - 20
- 4 **B.A.Kallmann**, H.Kolb, M.Hüther, S. Martin, M.Hellermann, E.F.Lampeter
Interleukin-10 is a predominant cytokine in atopic dermatitis.
Archives of Dermatology 1996; 132: 1133-1134
- 5 **B.A.Kallmann**, M.Hüther, M.Tubes, J.Feldkamp, J.Bertrams, F.A.Gries, E.F.Lampeter, H.Kolb
Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves' disease
Diabetes 1997; 46: 237-243
- 6 P.Rieckmann, B.Altenhofen, A.Riegel, **B.A.Kallmann**, K.Felgenhauer
Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis
Multiple Sclerosis 1998; 4: 178-182
- 7 **B.A.Kallmann**, E.F.Lampeter, P.Hanifi-Moghaddam, M.Hawa, R.D.G.Leslie, H.Kolb
Cytokine secretion patterns in twins discordant for type I diabetes
Diabetologia 1999; 42: 1080-1085
- 8 **B.A.Kallmann**, R.Malzkorn, H.Kolb
Exogenous nitric oxide modulates cytokine production in human leucocytes
Life Sciences 1999; 65: 1787-1794
- 9 P.Rieckmann, **B.A.Kallmann**:
Immunological parameters and magnetic resonance imaging activity
Frontiers in Multiple Sclerosis 1999; 2, Ed. A.Siva, J.Kesselring, A.J.Thompson, Martin Dunitz Ltd.: 117-125
- 10 P.Rieckmann, S.Jung, A.Chan, **B.A.Kallmann**, S.Martin
Pathogenesis and therapeutic concepts of organ-specific autoimmune diseases
Autoimmunity 1999; 31: 283-288
- 11 **B.A.Kallmann**, V.Hummel, T.Lindenlaub, K.Ruprecht, K.V.Toyka, P.Rieckmann
Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1
Brain 2000; 123: 687-697
- 12 V.Hummel, **B.A.Kallmann**, T.Füller, S.Wagner, A.Bayas, J.Tonn, E.Benveniste, K.V.Toyka, P.Rieckmann
The production of MMPs in human cerebral endothelial cells and their role in shedding of adhesion molecules
Journal of Neuropathology and Experimental Neurology 2001; 60: 320-327
- 13 **Multiple-Sklerose-Therapie-Konsensus-Gruppe**
Immunmodulatorische Stufentherapie der Multiplen Sklerose. 1. Ergänzung: Dezember 2000
Nervenarzt 2001; 72: 150-157
- 14 **Multiple-Sklerose-Therapie-Konsensus-Gruppe**
Immunmodulatorische Stufentherapie der Multiplen Sklerose. Neue Aspekte und praktische Umsetzung, März 2002
Nervenarzt 2002; 73: 556-563

- 15 **B.A.Kallmann**, S.Wagner, V.Hummel, A.Bayas, J.C.Tonn, P.Rieckmann
Characteristic gene expression profile of primary human cerebral endothelial cells
FASEB J Express, February 12, 2002, 10.1096/fj.01-0594fje
- 16 A.Bayas, V.Hummel, **B.A.Kallmann**, C.Karch, K.V.Toyka, P.Rieckmann
Human cerebral endothelial cells are a potential source for bioactive BDNF
Cytokine 2002; 19 (2): 55-58
- 17 P.Flachenecker, T.Kümpfel, **B.A.Kallmann**, M.Gottschalk, O.Grauer, P.Rieckmann, C.Trenkwalder, K.V.Toyka
Fatigue in multiple sclerosis: A comparison of different rating scales and correlation to clinical parameters
Multiple Sclerosis 2002; 8: 523-526
- 18 U. Michel, **B.A.Kallmann**, P. Rieckmann , D. Isbrandt
UM 9(5)h and UM 9(5)p, a human and a porcine non-coding transcript with preferential expression in the cerebellum
RNA 2002; 8: 1538-1547
- 19 **B.A.Kallmann**, P.Rieckmann
Chemokines and MS lesion development
International Journal of Multiple Sclerosis 2002; 9: 100-107
- 20 G.Martino, L.Adorini, P.Rieckmann, J.Hillert, **B.A.Kallmann**, G.Comi, M.Filippi
Inflammation in multiple sclerosis: the good, the bad, and the complex
Lancet Neurology 2002; 1: 499-509
- 21 **B.A.Kallmann**, P.Rieckmann
Was gibt es Neues in der Multiplen Sklerose?
Akt Neurologie 2003; 30: 421-427
- 22 **B.A.Kallmann**, J.Sauer, M.Schließer, M.Warmuth-Metz, P.Flachenecker, G.Becker, P.Rieckmann, M.Mäurer
Determination of ventricular diameters in multiple sclerosis patients with transcranial sonography (TCS) – A two year follow-up study
J Neurol 2004; 251: 30-34
- 23 **Multiple Sclerosis Therapy Consensus Group**
Escalating immunotherapy of multiple sclerosis. New aspects and practical application
Journal of Neurology 2004; 251: 1329-1339
- 24 P.Rieckmann, **B.A.Kallmann**
Neue Therapieansätze bei Multipler Sklerose
Nervenheilkunde 2005; 4: 294-300
- 25 **B.A.Kallmann**, S. Büttner, K.V. Toyka, K.Reiners, P. Rieckmann
Predictive value of evoked potentials for long term disease course in Multiple Sclerosis.
Multiple Sclerosis 2006; 12: 58-65
- 26 G. Valenza, **B.A.Kallmann**, A. Berend, R. Mlynki, K. Nöckler, O. Kurzai, M. Frosch, M. Abele-Horn
Isolation of Brucella melitensis from a patient with hearing loss
Eur J Clin Microbiol Infect Dis 2006; DOI 10.1007/s10096-006-0084-4
- 27 **Multiple-Sklerose-Therapie-Konsensus-Gruppe**
Immunmodulatorische Stufentherapie der Multiple Sklerose – aktuelle Therapieempfehlungen (September 2006)
Nervenarzt 2006; 77: 1506-1518
- 28 **Multiple Sclerosis Therapy Consensus Group**
Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations
J Neurol. 2008; 255:1449-1463
- 29 **Arbeitsgruppe Moderne Immuntherapie der MS des Ärztlichen Beirats der Deutschen Multiple Sklerose Gesellschaft**
Therapie der Multiplen Sklerose mit monoklonalen Antikörpern

55 Mathias Mäurer, Uwe Meier, Mike P.Wattjes, Tjalf Ziemssen, Heinz Wiendl, Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) [Ambulante spezialfachärztliche Versorgung \(ASV\) für die Multiple Sklerose.](#) DGNurologie (August 2023) <https://doi.org/10.1007/s42451-023-00594-4>

56 Kallmann BA, Eulenburg G, Kullmann J, Mäurer M. [TAURUS-MS II: Real-World Use of Teriflunomide in Germany and Changes in Treatment Patterns Over Time](#) Therapeutic Advances in Neurological Disorders, accepted for publication

57 Matthias Schwab, Andrew Chan, Anna-Katharina Eser, Boris Kallmann, Dieter Pöhlau, Joachim Richter, Torsten Wagner, Christoph Grothe
REBISTART: adherence of multiple sclerosis patients to treatment with subcutaneous interferon beta in the context of a patient support program
Neurology and Therapy, <https://doi.org/10.1007/s40120-024-00593-x>